Torrent Pharmaceuticals has informed the stock exchanges that it has scheduled a teleconference with investors and analysts on 22nd May, 2026 at 06:30 P.M. The call is intended to discuss the company's financial performance for the quarter and year ended 31st March, 2026. The announcement was made via a regulatory filing dated 12th May, 2026, signed by Company Secretary Chintan M. Trivedi.

Conference Call Dial-In Details

Participants can join the call using the following dial-in options:

International Toll-Free Numbers

The company has also provided country-specific toll-free access numbers for international participants, as detailed below:

Diamond Pass Registration

In addition to the dial-in options, Torrent Pharmaceuticals has provided a Diamond Pass Registration Link for participants who wish to register in advance for the conference call. The registration can be completed at the following link:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6264858&linkSecurityString=33fb010348

The filing was submitted to both BSE Limited and the National Stock Exchange of India Ltd. in compliance with the applicable listing regulations. The company is headquartered at Avirat, Thaltej Shilaj Road, Ahmedabad – 380059, and can be reached at investorservices@torrentpharma.com for investor-related queries.

J.B. Chemicals & Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have each filed separate disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the stock exchanges of a Notice of Hearing of Petition in connection with the proposed Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders. Both disclosures were made on 11th May 2026 and were accompanied by newspaper advertisement cuttings published in Indian Express (English) — all India Editions and Sandesh, Divya Bhaskar & Gujarat Samachar (Gujarati) — all in Gujarat Editions on 11th May 2026.

Amalgamation Petition Before NCLT

A Company Petition under Sections 230 and 232 and other applicable provisions of the Companies Act, 2013 has been filed for sanctioning the Scheme of Arrangement in the nature of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (Petitioner Transferor Company / JB Pharma) with Torrent Pharmaceuticals Limited (Petitioner Transferee Company / Torrent Pharma) and their respective shareholders. The key procedural milestones in the petition process are outlined below:

Details of the Petitioner Companies

The two companies involved in the proposed amalgamation are both incorporated under the Companies Act, 1956 and are registered in the State of Gujarat. Their details are as follows:

Participation and Representation Process

Any person seeking to support or oppose the Company Petition at the hearing is required to submit an affidavit with the grounds of support or opposition in the form of a representation before the Hon'ble Tribunal. Such persons must also provide a written copy to the Petitioner Companies' Advocate, Swati Soparkar, at 301, Shivalik-10, Opp. SBI Zonal Office, Near Old Excise Chowky, S.M. Road, Ambavadi, Ahmedabad – 380 015, and/or at swati.soparkar@gmail.com .

Copies must also be addressed to the respective Company Secretaries and Compliance Officers of both petitioner companies:

• JB Pharma: Mr. Sandeep Phadnis, Company Secretary & Compliance Officer, Neelam Centre, 'B' Wing, 4th floor, Hind Cycle Road, Worli, Mumbai 400030
• Torrent Pharma: Mr. Chintan Trivedi, Company Secretary & Compliance Officer, Avirat, Thaltej Shilaj Road, Ahmedabad – 380 059, Gujarat, India

All representations must be received no later than two days before the date fixed for the hearing of the Company Petition. Interested parties may appear in person or through their advocate. A copy of the Company Petition will be furnished to any person requiring the same on payment of the prescribed charges.

Regulatory Disclosure

The disclosure on behalf of Torrent Pharmaceuticals Limited was signed by Chintan M. Trivedi, Company Secretary, while the disclosure on behalf of J.B. Chemicals & Pharmaceuticals Limited was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary. Both submissions were made to BSE Limited and the National Stock Exchange of India Ltd. on 11th May 2026, in compliance with applicable SEBI listing regulations.